Incidence of inhibitor development in a group of young hemophilia A
patients treated exclusively with lyophilized cryoprecipitate
K Peerlinck, FR Rosendaal and J Vermylen
Center for Thrombosis and Vascular Research, University of Leuven, Belgium.
The incidence of neutralizing isoantibody formation to infused factor VIII
in a cohort of 67 hemophilia A patients, born between January 1, 1971 and
April 30, 1990, who had been treated exclusively with lyophilized
cryoprecipitate, was 6% (5.3 per 1,000 patient years of observation). The
age-dependent cumulative risk was 4.6% at 4 years of age and 6.7% at 8
years of age. Recent reports in patients treated with a variety of more
pure concentrates show a much higher incidence of inhibitor formation and
tend to be used as a reference when new concentrates are introduced. We
believe that a patient group, such as the one studied here, is a more
suitable reference population because these patients have been exclusively
treated with a single factor VIII preparation.
Volume 81,
Issue 12,
pp. 3332-3335,
06/15/1993
Copyright © 1993 by The American Society of Hematology
